Quest Diagnostics, Inc (NYSE: DGX)’s stock price has dropped by -3.53 in relation to previous closing price of 172.45. Nevertheless, the company has seen a loss of -0.03% in its stock price over the last five trading days. prnewswire.com reported 2025-03-19 that Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms guidance for full year 2025 SECAUCUS, N.J., March 19, 2025 /PRNewswire/ — At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company’s strategies to drive sustainable growth and deliver long-term shareholder value.
Is It Worth Investing in Quest Diagnostics, Inc (NYSE: DGX) Right Now?
The price-to-earnings ratio for Quest Diagnostics, Inc (NYSE: DGX) is above average at 21.61x. The 36-month beta value for DGX is also noteworthy at 0.77. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 10 rating it as “hold,” and 0 rating it as “sell.”
The public float for DGX is 110.35M, and at present, short sellers hold a 2.32% of that float. The average trading volume of DGX on March 19, 2025 was 1.05M shares.
DGX’s Market Performance
DGX’s stock has seen a -0.03% decrease for the week, with a -1.94% drop in the past month and a 7.33% gain in the past quarter. The volatility ratio for the week is 2.21%, and the volatility levels for the past 30 days are at 2.22% for Quest Diagnostics, Inc The simple moving average for the last 20 days is -3.33% for DGX’s stock, with a simple moving average of 7.95% for the last 200 days.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Citigroup repeating the rating for DGX by listing it as a “Neutral.” The predicted price for DGX in the upcoming period, according to Citigroup is $185 based on the research report published on March 04, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see DGX reach a price target of $174, previously predicting the price at $169. The rating they have provided for DGX stocks is “Outperform” according to the report published on January 06th, 2025.
Morgan Stanley gave a rating of “Overweight” to DGX, setting the target price at $172 in the report published on December 17th of the previous year.
DGX Trading at 1.24% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.99% of loss for the given period.
Volatility was left at 2.22%, however, over the last 30 days, the volatility rate increased by 2.21%, as shares sank -3.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.42% upper at present.
During the last 5 trading sessions, DGX fell by -0.11%, which changed the moving average for the period of 200-days by +19.31% in comparison to the 20-day moving average, which settled at $172.09. In addition, Quest Diagnostics, Inc saw 10.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from PREVOZNIK MICHAEL E, who proposed sale 4,643 shares at the price of $170.00 back on Mar 17 ’25. After this action, PREVOZNIK MICHAEL E now owns shares of Quest Diagnostics, Inc, valued at $789,310 using the latest closing price.
Doherty Catherine T., the EVP, Regional Businesses of Quest Diagnostics, Inc, sale 5,370 shares at $174.13 during a trade that took place back on Mar 05 ’25, which means that Doherty Catherine T. is holding 68,068 shares at $935,078 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.32 for the gross margin
The net margin for Quest Diagnostics, Inc stands at 0.09. The total capital return value is set at 0.1. Equity return is now at value 13.24, with 5.74 for asset returns.
Based on Quest Diagnostics, Inc (DGX), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.02. The interest coverage ratio of the stock is 6.11.
Currently, EBITDA for the company is 1.91 billion with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.52. The receivables turnover for the company is 7.57for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.10.
Conclusion
In summary, Quest Diagnostics, Inc (DGX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
